Here’s a roundup of the latest coronavirus-related news.
The COVID-19 vaccination effort is picking up the pace in the US, with over 133.31 million administered doses and 14.2% of the population fully vaccinated against the virus as of March 25.
This week, the Data and Safety Monitoring Board (DSMB) shared concerns over outdated data from AstraZeneca’s COVID-19 vaccine clinical trial. Separately, some vaccine recipients have reported adverse effects, including a delayed large local reaction, from the Moderna and Pfizer vaccines.
Here’s a roundup of the latest coronavirus-related news:
AstraZeneca published an up-to-date analysis on Thursday of its phase 3 COVID-19 vaccine clinical trial data for AZD1222, overturning earlier data that was announced on Monday.
A recent study looked at the role of the influenza vaccine in COVID-19 susceptibility and severity.
The DSMB has shared concerns about data from AstraZeneca’s COVID-19 vaccine clinical trial, notifying the National Institute of Health’s (NIH) National Institutes of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, and the pharmaceutical company.
While the COVID-19 vaccine is currently being rolled out, some vaccine recipients are experiencing adverse effects, one of which includes a delayed large local reaction.
New interim data from AstraZeneca showed that its COVID-19 vaccine candidate had a 79% efficacy rate in preventing symptomatic cases in adults, with an 80% efficacy in those aged 65 and older, the company announced.
Most COVID-19 vaccine recipients complete the second dose of their series within the recommended interval, according to new findings published in the CDC’s Morbidity and Mortality Weekly Report.